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We followed up a series of 23 Parkinson’s disease (PD) patients who had performed an immersive virtual reality (VR) protocol
eight years before. On that occasion, six patients incidentally described visual hallucinations (VH) with occurrences of images not
included in the virtual environment. Curiously, in the following years, only these patients reported the appearance of VH later in
their clinical history, while the rest of the group did not. Even considering the limited sample size, wemay argue that VR immersive
systems can induce unpleasant effects in PD patients who are predisposed to a cognitive impairment.
1. Introduction
Nowadays, there is an increasing emphasis on the applica-
tion of technology in the assessment and rehabilitation of
neurological diseases and one of these technologies is Virtual
Reality (VR).While the literature is limited, there are research
programs studying this application specifically in Parkinson’s
disease (PD). As such, understanding the usefulness, the
limitations, and the considerations in the application of
the technology is important to both scientific and clinical
communities.
In the past few years, strong scientific production has
sustained the role played by external cues, such as visual ones,
in the multisensory rehabilitative approach to PD [1].
VR technologies combined with treadmill training have
been successfully used to ameliorate gait in PD [2–4] by
means of an attention-trigger strategy even if, in some cases, a
beneficial effect has been described as limited to PD subjects
at advanced stages of the disease [5, 6].
An occasional negative impact of immersive VR systems
on PD patients has been preliminarily reported also for the
postural control [7].
We previously [8, 9] reported the incidental experience
of visual hallucinations (VH) in six of 23 PD patients during
immersion in a VR environment in which their virtual
actions were tested in comparison with controls.
These observations generate the need to find a clinical
reason that may explain the unpleasant effects of VR immer-
sion and help us better understand where the positive effects
of VR technology end and the negative ones start.
A relationship between VH and cognitive impairment in
PD has been tentatively established: PD patients with VH
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Table 1: Location and characteristics of the hallucinations.
Patient
number Location and characteristics of the hallucinations
1 In gymnasium: unidentified animals on the wall
2 In gymnasium: a nest of bees, with the bees flyingaround
3 In gymnasium: children sitting at desk
4 In kitchen: a petrol pump
5 In supermarket: the woman is mistaken for a policeman
6 In supermarket: unidentified animals on the wall andon the floor
show a prolonged choice reaction and a stimulus discrimi-
nation deficit [10], as well as an increased risk of dementia
[11].
Aim of the present studywas to study retrospectively after
eight years all the 23 cases who participated in the first VR
study [9], in order to verify if that VH reported during the
virtual session may have some correlation with the actual
cognitive status.
2. Methods
In the 2005 study [8, 9], the aimwas to evaluate the behaviour
of 23 PD patients and 15 healthy controls in VR environments
reproducing daily living situations (i.e., supermarket, gym,
and kitchen) both after one-hour L-dopa (LD) intake and 12
hours after withdrawal of the LD.
PD patients performed their virtual actions worse than
the controls in terms of time of execution, exploration,
pointing, and precision in avoiding obstacles. None of the
controls complained of any disturbances, such as minor
transient effects (nausea or vertigo) or visual abnormalities.
Although none of the participants reported ever having
experienced VH, during the off-state virtual session, six PD
patients incidentally reported an occurrence of images not
included in the virtual environment (Table 1).
The “object” of VH was the same for all patients. Accord-
ing to their descriptions, it seems that in all cases the
patient preserved the insight that the hallucinated image was
inappropriate at that point of virtual navigation, but they did
not appear surprised or worried about this visual experience.
We reviewed the clinical history of all six patients who
experienced VH: none had previously reported anything
similar to illusions or sensations of presence or passage.
In 2013, we tried to follow up all 23 PD patients of
the previous study. According to an agreement between the
Local Association of Patients and the Division of Neurology
and Neurorehabilitation of the Istituto Auxologico Italiano
Piancavallo (Verbania), Italy, all patients may be visited at
least once per year. The visits included a clinical update
via a neurological exam (UPDRS motor part) [12] and
a neuropsychological battery, including Mini Mental State
Examination [13], Frontal Assessment Battery [14], and the
Neuropsychiatry Inventory Test [15].
Patients were retrospectively divided into two groups
according to the results of the first study: with VH (VRVH,
6 patients) and without VH (WVRVH, 17 patients).
In the VRVH group, one patient had died and one had
undergone deep brain stimulation surgery (but was still
included in the follow-up); in the second group (WVRVH),
four patients had died and two patients could not be found.
Thus, 5 of the 6 patients in the VRVH group and 11 of the
17 patients in the WVRVH group completed the follow-up
(Figure 1).
3. Results
While none of the patients in the WVRVH group presented
any hallucination in their clinical history, all six patients of
the VRVH group reported the appearance of VH during the
course of their disease. Curiously, the dead patient in the first
group developed VH during their clinical course, while the
four dead patients of the second group did not.
Demographics and clinical characteristics of the groups
at baseline and eight years later at the follow-up are shown in
Table 2 and Figure 2.
In Table 3, the classification table by logistic regression
shows no prediction of VH starting from neuropsychological
tests, while in Table 4 all the variables out of the logistic
regression equation are reported. From Table 3 it can be
seen that the neuropsychological tests (also reported in
Table 4) were not able to predict (based on the logistic
regression) VH a priori, highlighting that only VR was able
to make a prediction in this sense. In fact, according to
neuropsychological tests, the logistic regression forecasted
that no patients would report VH; however, during VR six
patients incidentally described VH confirmed eight years
later. This result makes how VR highlighted a phenomenon
that cannot be predicted with standard neuropsychological
tests evident.
4. Discussion
Even with the limited sample size in this study, we reported
a correlation between complaining of VH during a VR
immersion and further appearance of VH in the clinical
picture.
This finding leads us to two relevant observations
concerning VR technology: (1) it can potentially induce
unwanted effects in PD patients; and (2) there are questions
about its usefulness in predicting further development of VH
in PD.
4.1. Visual Hallucinations as Unwanted Effects of Virtual
Reality. To our knowledge, in the literature there are no
reports of unwanted effects concerning VR sessions for
PD patients; our findings seem to be in contrast with the
increasing claims of usefulness of VR in the rehabilitation
approach of these patients [2–4, 16].
One explanation is that most VR methodologies used
in rehabilitation programs for PD are not immersive or
projected-based systems that strongly reduce the sense of
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Figure 1: Experimental design.
Table 2: Demographics and clinical characteristics of groups at baseline and eight years later at follow-up.
VHVR (6) WVHVR (17) P
Age baseline 67 ± 7.5 65 ± 8.3 NS
Sex (m) 1 8 NS
Education 8.5 ± 3.8 9.5 ± 5.4 NS
MMSE Baseline 26.5 ± 1.7Follow-up 23.2 ± 3.3
Baseline 25.6 ± 2.9
Follow-up 22.3 ± 3.7
NS
NS
Hoehn/Yahr stage Baseline 2.8 ± 1.5Follow-up 4 ± 0
Baseline 2.8 ± 1.1
Follow-up 3.1 ± 0.7
NS
𝑃 < 0.005
UPDRS part III Baseline 34.1 ± 6.3Follow-up 51.2 ± 7
Baseline 34.9 ± 14.4
Follow-up 40.3 ± 11
NS
𝑃 < 0.007
L-dopa eq/die (mg/day) Baseline 683.3Follow-up 695
Baseline 788
Follow-up 633
NS
NS
DA therapy (%) Baseline 100Follow-up 100
Baseline 30
Follow-up 70
VH (%) Baseline 0Follow-up 100
Baseline 0
Follow-up 0
NPI Baseline 9.8 ± 8.20Follow-up 13.8 ± 7.8
Baseline 6.8 ± 5.8
Follow-up 8.3 ± 7.1
NS
NS
FAB Baseline 12.8 ± 3Follow-up 11.4 ± 2.3
Baseline 14.6 ± 2.7
Follow-up 13.4 ± 2.6
𝑃 < 0.04
𝑃 < 0.07
All values represent mean (SD, when not otherwise stated).
MMSE =Mini Mental State Examination; NPI = Neuropsychiatry Inventory; FAB = Frontal Assessment Battery; UPDRS part III = Unified Parkinson’s Disease
Rating Scale-subscale III; VH = visual hallucination in the real life.
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Figure 2: All variables show that all the patients eight years later worsened, but even more so for the patients who experienced virtual
hallucinations after eight years.
Table 3: Classification table by logistic regression showing no prediction of visual hallucination starting from neuropsychological tests.
Observed Predicted
No virtual hallucination Virtual hallucination Percentage correct
No virtual hallucination 17 0 100.0
Virtual hallucination 6 0 0.0
Table 4: Table showing that all the variables are not in the logistic
regression equation.
Score df. Sig.
Variables
Education .184 1 .668
H/Y stage .335 1 .563
UPDRS part III .017 1 .895
Eq daily dose .007 1 .935
MMSE .461 1 .497
FAB 2.837 1 .092
NPI 1.030 1 .310
Overall statistics 5.244 7 .630
presence, which may be considered a trigger for unwanted
effects, especially those regarding the visual system.
VR experiences are pooled by a common step-simulation
by the interaction [17]. One of the most critical features
that differentiates immersive VR from nonimmersive VR is
the sense of reality (better known as “sense of presence”
among experts in cybertherapy), which means that the
proband feels the virtual experience as real.
This feeling of presence, which in adult subjects is
modulated by the prefrontal cortex-visual system loop [18], is
strictly influenced by the sophistication of the used software.
4.2. Why Visual Hallucinations? Various pathogenic models
have been considered to explain VH in PD, such as the
hypersensitivity of mesolimbic receptors due to dopamin-
ergic denervation during a dopaminergic treatment [19],
the deregulation of external perception and internal image
production according to the dream imagery intrusion model
[20], a deficit in reality monitoring [21], or a processing
disruption across attentional networks [22].
VH are one of the most typical symptoms among
the behavioural disturbances observed in PD, affecting
about one-quarter of patients. Several descriptions reported
the presence of formed images as inanimate objects or
Parkinson’s Disease 5
indefinite/not fully formed images, sensation of presence
(persons-guardian angel), or simply illusions consisting of the
misinterpretation of images, with the overlap of humanoid or
animal tracts on animated objects [23].
Curiously, VH can also include the feeling of an abnormal
“presence” (a vague and erroneous perception that another
person or threat is present) or “passage” hallucinations
(transient undefined hallucinations that pass through the
periphery of the visual field) [24].
The presence of VH during VR immersion is an inter-
esting and unexpected finding, as few side effects following
immersion in VR have been previously reported in litera-
ture. Research conducted on a group of healthy individuals
evidenced transient reduced binocular vision after wearing
a head-mounted display for just ten minutes [25], which
was probably due to the generation of three-dimensional
visual space from two-dimensional images. Nausea has been
reported during 20-minute immersion periods and ten-
minute postimmersion periods, which has been attributed to
the incongruity between visual and vestibular motion cues
[26].
VH in VR navigation show similarities with VH usually
evoked in the clinical history of PD patients, such as pre-
served awareness, only a moderate impact of stress, and the
incidence of images resembling animals (three of six patients
in the present study).
The VH shown by our patients always occurred only
during “off-medication” periods.
Other authors [27] reported an impaired adaptation to
visuomotor perturbations in VR environments during off-
state, suggesting a hypofunctional state of the dopaminergic
retinal system and reflecting the same “on-off” dependence
alterations of visual abnormalities observed during recording
by contrast sensitivity, electroretinograms, and visual evoked
potentials in PD patients with motor fluctuations [16]. Fur-
thermore, it was also shown that vision fluctuates in parallel
withmotor fluctuations [28]. Some authors also reported that
VH tend to occur during times of low ambient stimulation,
most typically in the evening or when the patient is alone in a
quiet environment [29]. Finally, visual attention impairment
has been described in patients with VH with acquired eye
diseases [30].
We can argue that a reduced dopaminergic state is corre-
lated with an altered sense of presence, such as that observed
in children whose immature prefrontal brain structure would
lead them to an increased susceptibility for the experience
of presence [22]. Thus, as also reported by neurofunctional
studies [31], a dysfunction of the frontal areas associated
with the control of visual attention could predispose PD
patients to VH through an abnormal processing of relevant
and irrelevant visual stimuli.
4.3. Visual Hallucinations as Prediction of Cognitive Impair-
ment. Various prospective studies [11, 32, 33] have considered
VH a risk factor for dementia. When examined longitudi-
nally, VH affect more patients than is commonly assumed in
cross-sectional prevalence studies. Neuropsychological and
FDG-PET studies have demonstrated that visuoperceptual
impairment and early involvement of the posterior neocortex
may be risk factors for rapid symptomatic progression and
dementia in PD [34].
In the present study, the comparison between the two
groups shows that the L-dopa eq/die of theWVHVR patients
is substantially lower at the baseline than in the follow-up, so
that the Hoehn/Yahar stage and UPDRS part III score. These
datawould support the assumption that visual hallucinations,
cognitive impairment, and motor scores seem to run in the
same direction [10, 11].
However, our findings can only raise and not solve
the question of whether VR technology can potentially be
considered a useful tool to predict who could further develop
VH.
Indeed, our study is limited by the restricted number
of cases and by the fact that a repetition of the VR session
was not included in the clinical follow-up. Moreover, as
the VH were an unexpected side effect at that time, visual
performances (such as color discrimination and contrast
perception) of all patients have not been investigated.
5. Conclusions
In consideration of the growing use of VR in PD treatment,
the first intent of this paper is to alert the scientific commu-
nity about the possibility of unwanted effectswhen immersive
systems are used.
Moreover, we describe a link between past and further
occurrence of VH in VR and clinical history, respectively, but
only further controlled studies with larger numbers of cases
will lead to the answers.
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